Radiation drug trial aims to stall aggressive gut cancer
NCT ID NCT03972488
Summary
This study tested whether a targeted radiation drug called Lutathera, combined with a hormone therapy, works better than high-dose hormone therapy alone to control the growth of advanced neuroendocrine tumors in the digestive system. It involved 226 patients with more aggressive forms of this cancer who had not yet received certain other treatments. The main goal was to see if the Lutathera combination could keep the cancer from getting worse for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.di Bologna Policl.S.Orsola
Bologna, Italy
-
Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology
Reggio Emilia, Italy
-
Asan Medical Center - Oncology
Seoul, South Korea
-
Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology
Roma, Italy
-
BC Cancer Agency
Vancouver, Canada
-
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
-
CHU Paris Nord-Val de Seine
Clichy, France
-
CHU-Hôtel Dieu Service de Médecine Nucléaire
Nantes, France
-
Centre Hospitalier Universitaire de Quebec
Québec, Canada
-
Erasmus Medisch Centrum
Rotterdam, Netherlands
-
Fondazione Irccs Istituto Nazionale Tumori
Milan, Italy
-
Guys And St Thomas Hospital
London, United Kingdom
-
Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot
Lyon, France
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
-
IRCCS fondazione Pascale - Oncology
Naples, Italy
-
Ieo, Irccs
Milan, Italy
-
Institut Gustave Roussy
Villejuif, France
-
Institut du Cancer de Montpellier - Oncology
Montpellier, France
-
Istituto Oncologico Romagnolo
Meldola, Italy
-
Kings College Hospital - Oncology
London, United Kingdom
-
London Health Sciences Centre, University of Western Ontario - Oncology
London, Canada
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic - Oncology
Rochester, Minnesota, 55905, United States
-
Royal Free Hospital, London
London, United Kingdom
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
-
Seoul National University Hospital - Department of Internal Medicine
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System - Medical Oncology
Seoul, South Korea
-
Sunnybrook Health Sciences Centre
Toronto, Canada
-
UMC Utrecht - Oncology
Utrecht, Netherlands
-
USF - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Genova - Oncology
Genova, Italy
-
University of Iowa Hospitals and Clinics - Oncology
Iowa City, Iowa, 52242, United States
-
University of Kentucky UK Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Essen - Klinik für Nuklearmedizin
Essen, Germany
-
Weston Park Hospital
Sheffield, United Kingdom
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.